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Inhibition of tumour growth by lipoxygenase inhibitors
HJ Hussey and MJ Tisdale
Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK.
Summary The potential involvement oflipoxygenase metabolites in the tumour growth stimulatory activity of
arachidonic and linoleic acid has been studied using the 5-lipoxygenase inhibitors, BWA4C, BWB70C and
Zileuton. In vitro the former two agents were relatively potent inhibitors of growth ofmurine adenocarcinomas
(MACs) with IC50 values < 10 giM, whereas Zileuton was less effective. In vivo studies showed BWA4C to be an
effective inhibitor of the growth of both the MAC26 and MAC16 tumours at dose levels between 5 and
25 mg kg-' (b.d.). The growth rate of the MAC26 tumour was also decreased by BWB70C at 25 mg kg-,
whereas lower doses were either ineffective or stimulated tumour growth. This differential effect of the 5-
lipoxygenases inhibitors on tumour growth may arise from effects on the 12- and 15-lipoxygenase pathways. To
quantify the effect cells were labelled with [3H]arachidonic acid and the biosynthesis of 5-, 12- and 15-
hydroxyeicosatetraenoic acid (HETE) was analysed by high-performance liquid chromatography. All three
agents caused a decrease in 5-HETE production, although the effect was less pronounced with Zileuton. In
MAC26 cells both BWA4C and BWB70C caused a decrease in 12-HETE formation whereas Zileuton had no
effect on the other lipoxygenase pathways. The inhibitory effect of these agents on cell growth may result from
an imbalance of metabolism of arachidonic acid between the 5-, 12- and 15-lipoxygenase pathways.
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Dietary fat and in particular polyunsaturated fatty acids
(PUFAs) has been implicated as a mediator of tumour
development and growth particularly in lower animals
(Hopkins and Carroll, 1979). The type of PUFA appears to
be important as n-6 fatty acids may promote carcinogenesis,
whereas n-3 fatty acids may have tumour-inhibitory effects
(Karmali, 1987). Not all n-6 fatty acids stimulate tumour
growth as gamma-linoleic acid (GLA) caused an inhibition of
mammary tumour growth in mice when administered in the
form of evening primrose oil (Pritchard et al., 1989).
Epidemiological studies have shown a decrease in risk for
cancers of the colon and stomach among patients with
rheumatoid arthritis (Gridley et al., 1993). This result is
consistent with an inhibitory effect of non-steroidal anti-
inflammatory drugs on colon cancer development, possibly
through an interference with prostaglandin synthesis
(Marnett, 1992).
Growth of hepatoma 7288 CTC in rats has been shown to
be limited by the availability of a substance released from the
host fat store during lipolysis. Later studies showed this to be
linoleic (LA) and arachidonic acids (AAs) (Sauer and
Dauchy, 1988). We have shown that pure LA stimulated
the growth of a murine colon adenocarcinoma (MAC26) and
that there was a threshold dose for growth stimulation when
the LA reached 3.8% of the total caloric intake (Hussey and
Tisdale, 1994). This figure is close to the threshold level (4%
of the total energy level) required for mammary tumour
promotion in vivo (Ip et al., 1985) and is lower than the
recommended (BNF Task Force, 1992) human intake (6% of
total calories).
In vitro studies have shown that growth stimulation by
both LA and AA was effectively inhibited by the
lipoxygenase inhibitor BWA4C (Hussey and Tisdale, 1994).
Lipoxygenase products have been shown to stimulate cellular
proliferation either directly (Bandyopadhyay et al., 1988), or
as intermediates in the mitogenic signal pathway by growth
factors such as epidermal growth factor (EGF) (Glasgow and
Eling, 1990). In order to establish the importance of PUFA
metabolism through lipoxygenase pathways to tumour
growth in vivo the effect of lipoxygenase inhibitors on the
growth of established murine adenocarcinomas (MACs) has
been determined. In addition, an attempt has been made to
determine whether the 5-, 12- or 15-lipoxygenase pathway is
most important for tumour cell proliferation.
Materials and methods
Animals
Pure strain NMRI mice were bred in our own colony and fed
a rat and mouse breeding diet (Pilsbury, Birmingham, UK)
and water ad libitum. Male animals (average body weight
25-30 g and age 6 weeks) were transplanted with fragments
of the MAC16 or MAC26 tumour into the flank by means of
a trocar and fed the normal diet ad libitum. Initial tumour
volumes were between 72 and 128 mm3 and this was reached
between 12 and 14 days after transplantation. Animals were
randomised into groups of ten animals to receive either drug
or solvent (paraffin oil) (0.1 ml) twice daily by gavage.
Tumour dimensions were measured daily by means of
calipers and the volume was calculated from the formula:
Length x (width)2
2
The experiment was continued either until the tumour
volume reached 1000 mm3 (MAC26) or the animals had lost
25% of their body weight owing to cachexia (MAC16).
Tumour-bearing animals that became moribund or bearing
tumours that became ulcerative were humanely killed.
Chemicals
BWA4C and BW70C were kindly donated by Dr L Garland,
Wellcome Research Laboratories, Kent, UK. Both agents
were suspended in paraffin oil and administered by gavage
every 12 h in 0.1 ml aliquots. Zileuton was kindly donated by
Abbot Laboratories. RPMI-1640 tissue culture medium and
fetal calf serum were purchased from Gibco Europe (Paisley,
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UK). [5, 6, 8, 11, 12, 14, 15-3H(N)] arachidonic acid (sp. act.
6.8 TBq nmol-') was purchased from Dupont Ltd., Hert-
fordshire, U.K.
Tumour cell lines
The MAC16, MAC13 and MAC26 mouse colon adenocarci-
noma cell lines were derived from the solid tumours and
kindly donated by Professor J Double, University of
Bradford, Bradford, UK. Cells were maintained in RPMI-
1640 medium containing either 10% (MAC13 and MAC26 as
a monolayer) or 5% fetal calf serum (MAC16 in suspension)
under an atmosphere of 5% carbon dioxide in air. Cells for
growth experiments were seeded either at 0.5 x 104 cells ml-1
(MAC13 and MAC26) or 2 x 104 cells ml-' (MAC16). Cell
number was determined by means of a Coulter Electronic
Particle Counter (ZM).
Analysis of lipoxygenase metabolites ofarachidonate
Cells (5 x 106) were incubated with the drugs for 24 h before
labelling. The cells were washed with phosphate-buffered
saline (PBS) and resuspended in fresh medium containing
22.5 ,uCi [3H]arachidonic acid mixed with unlabelled arachi-
donic acid to a final concentration of 10 gUM. After 2 h at
37°C the incubation was terminated by the addition of 1 N
hydrochloric acid to acidify the cell suspension to pH 3.5.
The cells were separated by low-speed centrifugation (1500 g,
10 min) and were washed twice with PBS. The cells were
resuspended in PBS (0.8 ml) and sonicated for 4 x 15 s on ice.
The solution was acidified to pH 3.5 with 1 N hydrochloric
acid and chloroform-methanol (1:2, v/v) (3 ml) was added,
followed by vigorous mixing for 1 min. After 30 min at room
temperature chloroform (1 ml) was added, and, after
vigorous mixing, was followed by the addition of 0.001 N
hydrochloric acid (1 ml) and vortexing for another 10 s. After
centrifugation at 2000 g for 20 min at 4°C the chloroform
layer was removed and the aqueous phase was re-extracted
with chloroform (2 ml). The combined chloroform extracts
were evaporated under a stream of nitrogen and the residue
was dissolved in acetonitrile (0.1 ml) and stored under argon
at -70°C in the absence of light. Cell lipids were analysed by
reverse-phase high-performance liquid chromatography (RP-
HPLC) with a Waters j Bondapak C18 column
(3.9 x 300 mm) by an isocratic elution at 1.5 ml min-' with
58% acetonitrile-water-acetic acid (20:100:0.05 v/v) and
42% acetonitrile-acetic acid (100:0.05 v/v) (Liu et al., 1994).
Radioactivity and ultraviolet absorbance at 237 nm were
monitored. Peaks were identified based on the retention times
of authentic 5-, 12- and 15-HETE (Sigma Chemical Co.,
Poole, Dorset, UK). The amounts of HETEs were quantified
based on the specific activity of radiolabelled arachidonic
acid and the ratio of radiolabelled to unlabelled substrate.
Results
The effect of three 5-lipoxygenase inhibitors Zileuton,
BWA4C and BWB70C on growth of the MAC16, MAC13
and MAC26 cell lines is shown in Table I. Zileuton was
relatively ineffective at inhibiting cell proliferation in all three
cell lines, whereas both BWA4C and BWB70C were potent
inhibitors of cellular proliferation with IC50 values < 10 gM
Table Effect of 5-lipoxygenase inhibitors on growth of cells in vitro
IC50 (/1M)a
Cell line Zileuton BWB70C BWA4C
MAC16 58+ 15 5+0 4+1
MAC13 43+7 2+1 3+1
MAC26 58 +8 4+1 5+1
aConcentration of agent causing 50% inhibition of cell growth.
Results are means+ s.e.m. for nine determinations per value.
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Figure 1 Effect of oral administration of BWA4C (b.d. in
paraffin oil) on the growth of the MAC26 tumour in NMRI mice.
The experiment was initiated 9 days after tumour transplantation
and the starting tumour volume was 115+26mm3, which was
normalised to 100% on day 1. Animals were randomised to
receive solvent alone (x) or BWA4C at 5 (0), 10 (0) or 25
(E)mgkg-1. Differences from control values, a, P<0.05 and b,
P<0.01 were determined by two-way ANOVA followed by
Tuckey's test.
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Figure 2 Effect of oral administration of BWA4C on tumour
growth (a) and host body weight (b) in NMRI mice transplanted
with the MAC16 tumour. The experiment was initiated 12 days
after tumour transplantation (day 1) and the absolute tumour
volume was 48+7mm3, which was normalised to 100% on day 1.
Animals were randomised to receive solvent alone (x) or BWA4C
at 5 (-), 10 (0) or 25 (EI)mgkg-1. Differences from control
values ap<0.05 and bp<0.01 were determined by two-way
ANOVA followed by Tuckey's test.for all three cell lines. The potency of these two agents
suggested that they may be effective anti-tumour agents in
vivo.
The most effective vehicle for BWA4C was found to be
paraffin oil and when given orally every 12 h it had neither a
stimulatory or inhibitory effect on the growth of the MAC26
tumour. BWA4C was an effective inhibitor of the growth of
the MAC26 tumour at dose levels between 5 and 25 mg kg-'
(Figure 1). After 13 days of treatment the tumour volume in
animals administered 25 mg kg-1 BWA4C was only one-
third of the control group. At this dose level BWA4C also
effectively inhibited the growth of the cachexia-inducing
MAC16 tumour with a significant reduction in tumour
volume from days 8-12 after initiation of treatment (Figure
2a). There was no effect on host weight loss at this dose level
(Figure 2b), although lower doses significantly increased
weight loss and decreased the time to termination as
described in Materials and methods, in comparison with
animals treated with paraffin oil alone.
Administration of BWB70C at 25 mg kg-1 also decreased
the growth rate of the MAC26 tumour, with a significant
reduction in tumour volume 8-13 days after initiation of
treatment (Figure 3a). In contrast a dose level of 5 mg kg-'
caused an increase in tumour volume that became significant
from days 11 to 13 whereas at 10 mg kg-' the tumour
volume was the same as the control at all time points except
for day 13 when it was significantly increased. Administration
of LA (1 g kg-') caused an increase in tumour volume that
became significant between days 8 and 13 (Figure 3b). This
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increase in tumour volume by LA was attenuated by
concomitant administration of BWB70C at dose levels of
10 and 25 mg kg-'.
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Figure 3 Effect of BWB70C on growth of the MAC26 tumour.
The experiment was initiated 9 days after tumour transplantation
and the starting tumour volume was 57 +9mm3, which was
normalised to 100% on day 1. Animals were randomised to
receive solvent alone (x) or LA (U) and BWA4C at 5 (@), 10 (0)
or 25 ([lI)mgkg-1 in the absence (a) and presence (b) of LA
(1gkg-'). In a differences from solvent control (aP<0.05 and
bp<0.01) and in b from LA (CP<0.05 and dp<0.01) were
determined by two-way ANOVA followed by Tuckey's test.
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Figure 4 Effect of preincubation of MAC16 ( ), MAC13 (C])
and MAC26 (m) cells with 1OpM BWA4C (a), BWB70C (b) and
Zileuton (c) on the percentage radiation recovered as AA, 5-
HETE, 12-HETE and 15-HETE after 2h labelling with
[3H]arachidonic acid. Differences from non-treated cells are
indicated as a, P<0.05 and b, P<0.01 and were determined by
two-way ANOVA followed by Tuckey's test.
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The differential effect of the three lipoxygenase inhibitors
on tumour growth may arise from a differential inhibition of
the 5-, 12- and 15-lipoxygenase pathways. The effect of these
agents on the accumulation of AA and distribution through
the three pathways after preincubation of MAC16, MAC13
and MAC26 cells with 10 gM of each of the inhibitors is
shown in Figure 4. The overall accumulation of AA and flux
through the three pathways was much lower for MAC16 than
the other two cell lines. Of the three agents only BWA4C
inhibited formation of 5-HETE in all three cell lines to a
similar extent (50%) whereas in MAC26 both 12- and 15-
HETE formation were inhibited by 60%. BWB70C, although
not significantly inhibiting 5-HETE formation in the MAC16
cell line, exerted more profound inhibition in the MAC13 and
MAC26 cell lines (75% and 62% respectively). Formation of
12-HETE, but not 15-HETE was also inhibited in the
MAC26 cell line. Zileuton only inhibited 5-HETE formation
in MAC13 and MAC26 cells by 35% and 42% respectively.
In contrast 12- and 15-HETE formation in MAC13 cells was
increased.
The effect of exogenous 5-, 12- and 15-HETE on growth
inhibition of MAC26 cells by 5 giM BWA4C is shown in
Figure 5. Only 15-HETE caused a significant reversal of
growth inhibition, whereas concentrations of 12-HETE
between 0.25 and 6.25 giM increased the growth-inhibitory
effect. There was little effect of 5-HETE. These results suggest
that inhibition of 15-lipoxygenase may account for the
growth-inhibitory effects, although imbalances between
production of 5-, 12- and 15-HETE also appear to result in
growth inhibition.
Discussion
The lipoxygenases constitute a family of non-haem iron-
containing dioxygenases that catalyse stereospecific oxygena-
tion of the 5-, 12- or 15-carbon atoms of AA to give the
corresponding 5-, 12- or 15-HETE. Although the biological
properties of the HETEs has not yet been fully evaluated
12(S)-HETE has been suggested as an important determinant
of the metastatic potential of tumour cells (Liu et al., 1994)
and to stimulate DNA synthesis of fetal bovine aortic
endothelial cells (Setty et al., 1987), an effect also
demonstrated by 15-HETE. The stimulation of cell prolifera-
tion and DNA synthesis may be brought about by inhibition
of diacylglycerol kinase, leading to an increase in the cellular
diacylglycerol level (Setty et al., 1987).
Although a large number of 5-lipoxygenase inhibitors have
been synthesised and evaluated (McMillan and Walker,
1992), there is a paucity of agents capable of specific
inhibition of the 12- or 15-lipoxygenase pathways. For this
reason 5-lipoxygenase inhibitors were used initially in
mechanistic studies in the hope that there would be some
cross-inhibition of the other two lipoxygenase pathways.
BWA4C was originally designed as an iron ligand inhibitor
of 5-lipoxygenase with an inhibitory activity 20 times stronger
than the cyclo-oxygenase inhibition (Tateson et al., 1988).
BWB70C is a hydroxyurea with the same mechanism of
action as BWA4C, but is not extensively metabolised in vivo
(Salmon and Garland, 1991). Zileuton has also been reported
to inhibit 5-lipoxygenase by iron chelation, but to be devoid
of both 12- and 15-lipoxygenase inhibitory properties (Carter
et al., 1991). This selectivity towards the 5-lipoxygenase
pathway has also been confirmed in tumour lines in vitro in
the present study. Despite the similarity in action of the three
agents towards the 5-lipoxygenase pathway they displayed
vastly different growth-inhibitory properties to three MAC
cell lines in vitro. Thus, although BWA4C and BWB70C
displayed IC50 values < 10 pM, the IC50 value of Zileuton was
five times higher for all cell lines. This suggested that the
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Figure 5 Effect of increasing concentrations of 5 (x), 12 (0) and
15-HETE (EJ) on growth of MAC26 cells treated with BWA4C
(S/ M). Results are means+s.e.m. for nine determinations per
value. Differences, a, P<0.01 from BWA4C using t-test followed
by Bonferroni correction.
inhibitory effect of the former two agents may be due to
inhibition of the 12- and/or 15-lipoxygenases. Using
radiolabelled AA to measure the amount of biosynthetic 5-,
12- or 15-HETE produced by the MAC cell lines in vitro all
three agents were shown to specifically inhibit 5-HETE
production, with BWA4C and BWB70C being most potent.
However, in the MAC26 cell line BWA4C also inhibited flux
through the 12- and 15-lipoxygenase pathways. BWB70C also
inhibited flux through the 12-lipoxygenase pathway in
MAC26, whereas Zileuton either had no effect (MAC26) or
stimulated flux through the 12- and 15-lipoxygenase path-
ways (MAC13).
Growth inhibition by lipoxygenase inhibitors may reside in
an alteration in flux through the respective pathways rather
than inhibition of a specific pathway as the addition of
exogenous 12-HETE to MAC26 cells actually increased the
growth-inhibitory effect of BWA4C. There was, however, a
significant reversal of growth inhibition at concentrations of
15-HETE > 1.5 jIM. It is likely that there are complex
interactions between the competing lipoxygenase pathways.
These results suggest that metabolism of LA and AA
through the lipoxygenase pathways is important to tumour
growth and that an imbalance of metabolism through the 12-
or 15-pathways may result in growth inhibition. The efficacy
of BWA4C towards established murine adenocarcinomas,
which are generally considered to be chemoresistant at dose
levels not causing host toxicity, suggests a new type of anti-
cancer therapy based on lipoxygenase inhibition.
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